Optimizing colorectal cancer screening by getting FIT right

Gastroenterology

Volumn 141, Issue 5, 2011, Pages 1551-1555

  Levin, Theodore R ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ADENOMA; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; COLONOSCOPY; COLORECTAL CANCER; EDITORIAL; ELECTRONIC MEDICAL RECORD; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOASSAY; OCCULT BLOOD TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY;

EID: 80054858467     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.09.021     Document Type: Editorial

References (25)

1. Richardson LC, Tai E, Rim SH, et al. Vital Signs: colorectal cancer screening, incidence, and mortality - United States, 2002-2010. MMWR Morb Mortal Wkly Rep 2011;60:884-889.
2. Naishadham D, Lansdorp-Vogelaar I, Siegel R, et al. State disparities in colorectal cancer mortality patterns in the United States. Cancer Epidemiol Biomarkers Prev 2011;20:1296-1302.
3. O'Malley AS, Forrest CB, Feng S, et al. Disparities despite coverage: gaps in colorectal cancer screening among Medicare beneficiaries. Arch Intern Med 2005;165:2129-2135.
4. Doubeni CA, Laiyemo AO, Reed G, et al. Socioeconomic and racial patterns of colorectal cancer screening among Medicare enrollees in 2000 to 2005. Cancer Epidemiol Biomarkers Prev 2009;18:2170-2175.
5. Doubeni CA, Laiyemo AO, Young AC, et al. Primary care, economic barriers to health care, and use of colorectal cancer screening tests among Medicare enrollees over time. Ann Fam Med 2010;8:299-307.
6. Benuzillo J, Jacobs E, Hoffman R, et al. Rural-urban differences in colorectal cancer screening capacity in Arizona. J Community Health 2009;34:523-528.
7. Inadomi JM, Vijan S, Janz NK, et al. Method of recommendation for colorectal cancer screening strategies impacts adherence. Gastroenterology 2010;138:S-23.
8. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009;104:739-750.
9. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:130-160.
10. Benson VS, Patnick J, Davies AK, et al. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer 2008;122:1357-1367.
11. US Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2008;149:627-637.
12. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659-669.
13. Levin TR, Jamieson L, Burley DA, et al. Organized colorectal cancer screening in integrated health care systems. Epidemiologic Reviews 2011;33:101-110.
14. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82-90.
15. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-68.
16. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007;99:1462-1470.
17. Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-159.
18. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010;105:2017-2025.
19. Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:638-658.
20. Wilschut JA, Hol L, Dekker E, et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011;141:1648-1655.
21. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103-1110.
22. van Rossum LG, van Rijn AF, Laheij RJ, et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer 2009;101:1274-1281.
23. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-255.
24. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009;101:1412-1422.
25. Parekh M, Fendrick AM, Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 2008;27:697-712.